![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The proceeds will advance RBT-1 through a pivotal Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surgery. RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Product Name: RBT-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Juniper Point
Deal Size: $72.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 12, 2023
Details:
RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways that is advancing toward for its lead indication to reduce post-operative complications following cardiothoracic surgery.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Product Name: RBT-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
RBT-1 (Iron sucrose), treated patients demonstrated a highly significant increase in anti-inflammatory and antioxidant biomarkers of cytoprotective preconditioning. The biomarkers assessed were interleukin-10, heme oxygenase-1 and ferritin.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Product Name: RBT-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
RBT-1 (Iron Sucrose) met primary endpoint of increasing the expression of biomarkers of cytoprotective preconditioning; positive data supports the potential for RBT-1 to impact clinical outcomes in cardiothoracic surgery patients.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Product Name: RBT-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2022
Details:
Proceeds from the recent financing will be used to advance Renibus’ pipeline, including the company’s lead candidates, RBT-1 for prevention of acute kidney injury (AKI), currently in a large (126 patients), randomized, double-blind study in AKI in a cardiac surgery setting.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Product Name: RBT-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 15, 2022
Details:
This Phase 2 study will evaluate the efficacy of RBT-1 in generating a preconditioning response as measured by a composite of biomarkers in subjects who are at risk for AKI following cardiac surgery.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: RBT-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2021
Details:
Rénibus Therapeutics will present Phase 1b clinical trial data on RBT-1, its investigational treatment for the prevention of acute kidney injury (AKI), at the Acute Kidney Injury & Continuous Renal Replacement Therapy (AKI & CRRT) 2021 Conference.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: RBT-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2021
Details:
RBT-9 initially showcased broad antiviral activity against several enveloped viruses – as well as protective effects for vital organs, including the lungs, heart, kidneys and liver. RBT-9 inhibits viral activity of SARS-CoV-2, shows study conducted by NIAID.
Lead Product(s): Stannus Protoporphyrin
Therapeutic Area: Infections and Infectious Diseases Product Name: RBT-9
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2020
Details:
RBT-9 is being developed by Renibus Therapeutics as an antiviral agent with organ-protective attributes. With the advent of the coronavirus pandemic, Renibus scientists moved quickly to plan and initiate a clinical trial of RBT-9 in COVID-19 patients.
Lead Product(s): Stannus Protoporphyrin
Therapeutic Area: Infections and Infectious Diseases Product Name: RBT-9
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Renibus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 24, 2020
Details:
Preclinical studies have shown that RBT-9 protects various organs, including the lung, heart, kidney, and liver. Importantly, RBT-9 has demonstrated antiviral activity in several enveloped viruses and inhibits a key mediator of viral replication in coronaviruses.
Lead Product(s): Stannus Protoporphyrin
Therapeutic Area: Infections and Infectious Diseases Product Name: RBT-9
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
Details:
Cascade Chemistry has been selected by Renibus Therapeutics, to produce the API for clinical trial supplies of RBT-9, an investigational therapy entering a Phase 2 trial for the treatment of high risk COVID-19 patients.
Lead Product(s): Stannus Protoporphyrin
Therapeutic Area: Infections and Infectious Diseases Product Name: RBT-9
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Renibus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 16, 2020
Details:
Based on the results to be presented at ERA-EDTA, the company is currently planning a Phase 2 study to investigate whether RBT-1 upregulates the expression of these biomarkers of cytoprotection in patients scheduled to undergo cardiac surgery.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020